JNJ · 10-Q · 2026Q2 · Full report

Oncology Product Growth

JOHNSON & JOHNSON · 2026-07-23 · Importance 65 · Surprise 48 · In source text

Innovative Medicine oncology sales increased 19.9% to $14.4 billion in fiscal six months 2026, with 16.9% operational growth. DARZALEX grew 20.6% on strong share gains and market growth, while CARVYKTI increased 55.1% on continued share gains and site expansion. TECVAYLI benefited from launch uptake, the U.S. TECVAYLI plus DARZALEX FASPRO approval, and expansion in community settings; TALVEY and RYBREVANT/LAZCLUZE also gained share through community expansion and launch uptake. Growth was partly offset by IMBRUVICA, which declined 12.9% because of competitive share loss and unfavorable patient mix.

Key facts

• Oncology achieved total sales of $14,379 million for the fiscal six months ended June 28, 2026 representing a 19.9% total change, 16.9% operations change and 3.0% currency change versus prior year. source
• DARZALEX sales were $8,171 million for the fiscal six months ended June 28, 2026, a 20.6% total change, 17.7% operations change and 2.9% currency change versus prior year. source
• CARVYKTI sales grew 55.1% total (52.1% operations, 3.0% currency) in the fiscal six months ended June 28, 2026. source

Impact estimates